- Editorials Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score? Editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease”
- Michael Kwan-Lung Ko, Loey Lung-Yi Mak
- DOI: 10.3350/cmh.2025.0118 [Epub ahead of print]
- Original Articles Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters
- Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen
- DOI: 10.3350/cmh.2024.0724 [Epub ahead of print]
- Reviews Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B
- Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
- Clin Mol Hepatol. 2025;31(Suppl):S182-S195.
- Prospect of emerging treatments for hepatitis B virus functional cure
- Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2025;31(Suppl):S165-181.
- Editorials MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
- Rex Wan-Hin Hui, Lung-Yi Mak
- Clin Mol Hepatol. 2025;31(1):290-292.
- Steatotic liver disease: Know your enemies
- Lung-Yi Mak
- Clin Mol Hepatol. 2024;30(2):171-173.
- Reviews The role of different viral biomarkers on the management of chronic hepatitis B
- Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(2):263-276.
- Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
- Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(2):217-229.
- Screening strategy for non-alcoholic fatty liver disease
- Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
- Clin Mol Hepatol. 2023;29(Suppl):S103-S122.
- Correspondences Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”
- Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(1):191-193.
- Original Articles Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
- Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2023;29(1):146-162.
- Reviews RNA interference as a novel treatment strategy for chronic hepatitis B infection
- Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
- Clin Mol Hepatol. 2022;28(3):408-424.